Innavac is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.
Innavac’s novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
Key potential applications for Innavac’s new agents include the prevention of respiratory infection in hospital settings and for at-risk populations in the community. Patients with pre-existing lung diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, as well as infants and young children, the elderly and patients with immune suppression are envisaged to be the future beneficiaries of this technology.
Innavac’s TLR2 agonists are also being developed as the next-generation adjuvant for recombinant protein and peptide-based vaccines. Designed to deliver vaccine cargo to antigen presenting cells through their surface expressing TLR-2, the use of Innavac’s adjuvant results in potent cytotoxic CD8+ T cell and antibody responses.